However, it is not well understood at this time whether the co-administration of certain medications may influence prescribing choices among patients with type 2 diabetes. The concomitant use of loop diuretics and SGLT2is, for example, should be avoided because of the potential risk of volume depletion in patients. In a time of emerging treatment options that may offer benefits to patients with cardiorenal disease complications, there is an increasing need to understand the impact of the choice of medications according to other clinical conditions. The increasing prevalence of cardiovascular and renal diseases in patients with type 2 diabetes has led to a broader disease management goal of reducing adverse clinical complications in patients with type 2 diabetes. People with an eGFR of less than 60 mL/min/1.73 m 2 are excluded for initiation of SGLT2is, and an eGFR of less than 45 mL/min/1.73 m 2 is the level to withdraw this medication. This mode of action has been the trigger to use an estimated glomerular filtration rate (eGFR) as a threshold for their use. Hence, their effectiveness in reducing hyperglycaemia relies upon normal renal glomerular-tubular function, which diminishes in people with renal impairment. SGLT2is have a unique mode of action and are classified as insulin independent that prevent the reabsorption of glucose, thereby facilitating its excretion in urine. Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are increasingly prescribed in the management of type 2 diabetes either as initial monotherapy in persons who cannot tolerate metformin or as add-on to metformin and other glucose-lowering drugs. The study will inform how SGLT2is are prescribed in real-world clinical practice according to renal function and a history of heart failure Additionally, we will explore whether renal function and heart failure are independently associated with SGLT2i inhibitor prescribing We will conduct a cross-sectional analysis using the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database to calculate the percentage of people prescribed SGLT2is according to their renal function, presence of heart failure (stratified by body mass index), and co-prescribing of diuretics. The study protocol describes our planned methods to describe the clinical characteristics of people with type 2 diabetes prescribed SGLT2is in English primary care, with a specific focus on renal function and heart failure diagnosis However, recent evidence from clinical trials confirm that SGLT2is have renal and heart failure benefits that are independent of the glucose-lowering effects, and it is currently unknown whether the presence of these clinical conditions may influence prescribing choices in individuals with type 2 diabetes The Reinforced Concrete Council and the Ready Mixed Concrete Bureau are now part of The Concrete Centre.Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are not recommended in people with impaired renal function as a result of their reduced efficacy for improving glycaemic control in this group Funded by 15 major cement and concrete organisations, the Concrete Centre works alongside the British Cement Association, The Concrete Society, and the ready mix and precast concrete industries to ensure an integrated approach from the concrete sector to technical support, research, education, training and information services. Their aim is to enable all those involved in the design, use and performance of concrete to realise the potential of the material. The Concrete Centre is the central development organisation for the UK concrete sector and provides material, design and construction guidance. Revisions required to Worked Examples to Eurocode 2 due to Amendment 1 to NA to BS EN :2004 dated Dec 2009. Superseded by 'Worked examples to Eurocode 2' (TCC, 2009) which removed reference to a second volume that was never published. Gives practical guidance on the use of BS EN in the design of in-situ concrete building structures, including how to calculate to Eurocode 2. Withdrawn, Document not available for download
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |